KIT and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib monotherapy is FDA-approved for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia and Kit-positive unresectable malignant gastrointestinal stromal tumors (Demetri et al. 2002; Peng et al. 2005; Berman et al. 2013).